Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasm Metastasis 6Lymphoma, Extranodal NK-T-Cell 6Carcinoma, Hepatocellular 5Stomach Neoplasms 3Nasopharyngeal Carcinoma 3Locally Advanced Rectal Cancer 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumor 3Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Nasopharyngeal Neoplasms 2Melanoma 2Epstein-Barr Virus Infections 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Osteosarcoma 1Objective Response Rate 1NSCLC 1Muscle-Invasive Bladder Carcinoma 1Lymphoma, T-Cell 1Lymphoma 1Kidney Neoplasms 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 5fludarabine 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Gemcitabine 3fludarabine phosphate 2endostar protein 2Melphalan 2Etoposide 2Doxorubicin 2Cisplatin 2Alemtuzumab 2thymoglobulin 1spartalizumab 1selinexor 1pembrolizumab 1Vindesine 1Vincristine 1Sensitivity and Specificity 1Rituximab 1Prednisone 1Prednisolone 1Methylprednisolone 1Interleukin-2 1Flavin-Adenine Dinucleotide 1Epirubicin 1Endostatins 1Drug Therapy 1Dexamethasone 1Cytarabine 1Clinical Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, T-Cell × spartalizumab × Clear all
NCT05821192 2023-04-20

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

The First Hospital of Jilin University

Phase NA Unknown
34 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡